Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice

Vladislav Volarevic1, Marija Milovanovic, Biljana Ljujic

  • 1Center for Molecular Medicine and Stem Cell Research, Faculty of Medicine, University of Kragujevac, Kragujevac, Serbia.

Abstract

Insights

Galectin-3 (Gal-3) promotes liver inflammation and damage in concanavalin A (Con A)-induced hepatitis. Inhibiting Gal-3 reduces liver injury, inflammatory cell infiltration, and apoptosis, suggesting Gal-3 as a therapeutic target.

Area of Science:

  • Immunology
  • Hepatology
  • Molecular Biology

Background:

  • Concanavalin A (Con A)-induced hepatitis is a model for studying immune-mediated liver injury.
  • Galectin-3 (Gal-3) is implicated in inflammatory processes, but its specific role in Con A-induced hepatitis is not fully understood.

Purpose of the Study:

  • To investigate the role of Gal-3 in Con A-induced liver injury.
  • To evaluate the therapeutic potential of Gal-3 inhibition in this model.

Main Methods:

  • Comparison of Con A-induced hepatitis in galectin-3-deficient (Gal-3(-/-)) mice and wild-type (WT) mice.
  • Treatment of WT mice with a selective Gal-3 inhibitor (TD139).
  • Assessment of liver enzymes, histology, immune cell infiltration (mononuclear cells, lymphocytes, dendritic cells), cytokine production (TNFα, IFNγ, IL-17, IL-4, IL-10), and apoptosis.

Main Results:

  • Gal-3(-/-) mice exhibited reduced sensitivity to Con A-induced hepatitis with lower immune cell activation and pro-inflammatory cytokine levels.
  • TD139 treatment attenuated liver injury, reduced inflammatory cell infiltration, and modulated cytokine profiles in WT mice.
  • Gal-3 deficiency and inhibition led to increased IL-10 production, alternative macrophage activation, and reduced apoptosis of liver-infiltrating cells.

Conclusions:

  • Gal-3 plays a significant pro-inflammatory role in Con A-induced hepatitis.
  • Gal-3 promotes T lymphocyte and NK T cell activation, dendritic cell maturation, pro-inflammatory cytokine secretion, M2 macrophage polarization suppression, and mononuclear cell apoptosis.
  • Targeting Gal-3 with inhibitors like TD139 shows therapeutic promise for mitigating liver inflammation and injury.

Related Concept Videos